MUSTANG BIO, INC. 8-K

What Happened

• On April 15, 2026, Mustang Bio, Inc. (MBIO) announced it received a notice from Nasdaq’s Listing Qualifications Staff that its common stock closed below $1.00 per share for 30 consecutive business days and is therefore not in compliance with Nasdaq Listing Rule 5550(a)(2). The notice does not have an immediate effect on the listing.

Key Details

• Nasdaq afforded a 180-calendar-day compliance period running through October 12, 2026, for Mustang Bio to regain compliance.
• To cure the deficiency during the period, the company must show a closing bid of at least $1.00 per share for a minimum of 10 consecutive business days (generally not more than 20).
• If not regained by October 12, 2026, the company may be eligible for a second 180-day period only if it meets Nasdaq’s initial listing criteria and market value requirements and notifies Nasdaq of intent to cure (for example, via a reverse stock split).
• If ineligible for a second period, Nasdaq may seek delisting but the company can request a hearing from the Nasdaq Hearings Panel to stay any delisting while the appeal proceeds.
• Mustang Bio said it will monitor the bid price and consider options but has made no decision yet.

Why It Matters

• A sustained failure to meet the $1 bid-price rule can lead to delisting, which would reduce liquidity and potentially limit investors’ ability to trade the stock on Nasdaq. The company has until October 12, 2026 to regain compliance or seek further relief under Nasdaq rules. Investors should watch the stock’s closing price and company announcements for any planned actions (e.g., reverse stock split) or updates on a Nasdaq hearing.